Context Therapeutics - Manufacturing agreement with Lonza for CTIM-76
Context Therapeutics has signed a manufacturing agreement with Lonza to develop CTIM-76 (active ingredient and final product form), its bispecific...
398 Views
Context Therapeutics - A catalyst-rich period ahead
Context Therapeutics has presented a recap of key highlights of 2022 as well as strategic priorities and operational guidance for 2023. The past...
616 Views
Context Therapeutics - Initial data from the SMILE study encouraging
Context Therapeutics has announced encouraging four-month progression-free survival (PFS) data from the Phase II SMILE trial, which is...
663 Views
Context Therapeutics - CTIM-76 selected as clinical CLDN6 candidate
In an encouraging pipeline development, Context Therapeutics has announced the selection of a final clinical candidate for its second R&D...
535 Views
Context Therapeutics - Period marked by readouts and pipeline progress
Context Therapeutics’ Q322 report focused on pipeline progress, reporting interim data from two Phase II trials (advanced endometrial and ovarian...
41 Views